Pharmacist Naloxone (or other opioid antagonist) Dispensing Guide

The New Mexico Department of Health has issued a statewide standing order allowing for all registered pharmacists in New Mexico to dispense opioid antagonists, such as naloxone, to individuals at risk of experiencing or witnessing an opioid overdose. Expanding access to opioid antagonists is a key component of opioid overdose prevention. As trusted and accessible health care professionals, pharmacists are in a unique position to educate individuals on opioid overdose and dispense opioid antagonists when indicated.

I. Eligible Candidates for Naloxone (or other opioid antagonist)

Naloxone (or other opioid antagonist) may be dispensed to:

• Anyone who uses an opioid regardless of how the opioid is used or obtained.
• Anyone in a position to assist a person at risk of an opioid overdose.

Factors to consider that increase risk for overdose:

• Using opioids for more than 3 months.
• Using opioids and benzodiazepines simultaneously.
• Being treated for opioid use disorder with buprenorphine or methadone.
• History of opioid overdose.
• Returning to opioid use after a period of abstinence.

Contraindications:

• Known hypersensitivity to naloxone. Anaphylactic shock may occur in those allergic to naloxone or any of its components. Contraindication(s) to other FDA approved opioid antagonist(s), if any, based on manufacturer’s drug information (approved product labeling) must be observed by pharmacist in determination of whether the product is appropriate.

II. Dispensing Information

The following naloxone products may be dispensed to individuals eligible to receive naloxone:

Product Selection and Labeling

<table>
<thead>
<tr>
<th>Naloxone Product and Quantity: Dispense one of the following naloxone products (or other opioid antagonist) based on product availability and individual’s request.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naloxone HCl Solution 1 mg/mL; 2 mL pre-filled Luer-Lock Syringe</td>
</tr>
<tr>
<td>Dispense: 2 x 2 mL syringes (4 mL total) with two nasal mucosal atomization devices.</td>
</tr>
<tr>
<td>Directions for use: Spray 1 mL (one-half of prefilled syringe) in each nostril. Repeat after 3 minutes if no response.</td>
</tr>
<tr>
<td>Narcan® Nasal Spray (naloxone HCl) 4 mg/0.1 mL Nasal Spray</td>
</tr>
<tr>
<td>Dispense: 1 box containing two 4 mg/0.1 mL doses of naloxone</td>
</tr>
<tr>
<td>Directions for use: Administer a single spray of Narcan® in one nostril. Repeat after 3 minutes if no response.</td>
</tr>
</tbody>
</table>

Any other naloxone preparation or opioid antagonist commercially available and FDA approved for the emergency treatment of known or suspected opioid overdose. Label with directions for use consistent with drug monograph. Call 911.

Prescription Label Requirements: Prescriptions for naloxone (or other opioid antagonist) should be labeled and processed in the same manner as all other prescriptions. Label must include: Name of recipient/person requesting naloxone (or other opioid antagonist), date dispensed, naloxone (or other opioid antagonist) product and quantity, licensed prescriber name and information, directions for use (sig), and refills: PRN.

Licensed Prescriber Information:

Chris Novak, MD
Address: 1190 S St. Francis Dr., Ste. S-1057
Santa Fe, NM 87505
NPI: 1508834110      License#: MD2009-0030

Updated 01/06/2022 – CT NMDOH
III. Naloxone Products and Insurance Billing

Naloxone HCl Solution 1 mg/mL; 2 mL pre-filled LL Syringe – NDC 76329-3369-01
Narcan® (naloxone HCl) 4 mg/0.1 mL Nasal Spray – NDC 69547-0353-02

New Mexico Medicaid (Centennial) plans-
Naloxone claims should adjudicate for reimbursement without prior authorization. Please see MCO billing information available on the NMPhA website: http://www.nmpharmacy.org/naloxone-resources

Medicare Part D and other non-Medicaid plans-
Currently some of these plans do cover naloxone products and the member pays a copay for the prescription.

IV. Opioid Overdose and Naloxone Education

The pharmacist should be familiar with opioid overdose prevention, using opioid medications safely, and naloxone administration instructions. Please use the following handout as a guide to educate and counsel individuals receiving naloxone. Review the information with the individual and provide a written copy of the handout with each naloxone product being dispensed.

User Guide - Information on Opioid Safety and How to Use Naloxone

Pharmacist training information: While current pharmacist naloxone training offered by NMPhA is not required to dispense naloxone under the NMDOH standing order, pharmacists are highly encouraged to take advantage of the valuable training programs NMPhA has to offer to further their education. NMPhA will be providing Naloxone Continuing Pharmacy Education and will continue to offer the Pharmacist Certification for Prescribing Naloxone training. Please see their website for further details.

V. Additional Resources

New Mexico Department of Health website: https://nmhealth.org/about/erd/ibeb/pos/
New Mexico Pharmacists Association website: http://nmpharmacy.org
Prescribe to Prevent website: http://prescribetoprevent.org
Link to SB 262/HB 277 Administration of Opioid Antagonists:

If you have any questions, please contact:

Chris Trujillo, PharmD
Prescription Drug Overdose Prevention
New Mexico Department of Health
(505)660-7373
ChristopherJ.Trujil@state.nm.us